Efficacy and safety of programmed cell death-1/programmed cell death ligand-1 inhibitors in advanced urothelial malignancy: A systematic review and meta-analysis

INTRODUCTION: Programmed cell death-1/programmed cell death ligand-1 (PD-1/PDL-1) inhibitors are the newest class of approved drugs for advanced urothelial cancer (AdUC). This review aims to collate the evidence for their efficacy and safety in various treatment settings. METHODS: Extensive search o...

Descripción completa

Detalles Bibliográficos
Autores principales: Pattanaik, Smita, Dey, Sumit, Jaiswal, Nishant, Rohilla, Rachna, Singh, Shrawan Kumar, Mandal, Arup Kumar, Mavuduru, Ravimohan Suryanarayan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458809/
https://www.ncbi.nlm.nih.gov/pubmed/31000914
http://dx.doi.org/10.4103/iju.IJU_357_18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458809/
https://www.ncbi.nlm.nih.gov/pubmed/31000914
http://dx.doi.org/10.4103/iju.IJU_357_18

Ejemplares similares